GT Biopharma sells USD 7.75 million: what it means for GT Biopharma stock

Published on 10/02/2026 at 02:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GT Biopharma disclosed USD 7.75 million sold on September 14, 2026 under Rule 506(b). For GT Biopharma stock, USD 31.21 million remains to sell.

GTBP, US36254L4077, Illustration mit AI erstellt.

GT Biopharma, Inc. (ISIN US36254L4077) disclosed USD 7.75 million sold in an equity offering dated September 14, 2026. For GT Biopharma stock, the filing also lists USD 31.21 million remaining to be sold, making financing capacity the clearest market fact in the latest disclosure.

Financing adds scale

According to StockTitan on September 29, 2026, the Form D notice describes a USD 38.96 million total offering, with USD 7.75 million sold and USD 31.21 million remaining. The filing identifies the securities as equity and cites the Rule 506(b) exemption.

The same filing reports 8,611.111 Series M preferred shares with an aggregate stated value of USD 8.61 million for the USD 7.75 million purchase price. The document also reports USD 0 in finders' fees, a concrete detail that separates gross financing from stated offering expenses.

Nasdaq status improves

GT Biopharma also regained compliance with Nasdaq's USD 1.00 minimum bid requirement. StockTitan reports that Nasdaq notified the company on September 22, 2026, after the common stock maintained a closing bid above USD 1.00 for 10 consecutive business days. The additional compliance period had been scheduled to run through November 16, 2026.

That sequence changes the immediate listing narrative, but it does not remove financing risk. The offering's remaining USD 31.21 million is more than four times the amount already sold, while the filing does not quantify the ownership effect for existing holders.

Pipeline remains clinical

GT Biopharma lists its latest news from September 15, 2026, when it announced FDA clearance of a new investigational application for GTB-5550 in multiple myeloma. The company says its GTB-5550 and GTB-3650 Phase 1 trials are actively enrolling.

The multiple myeloma program is planned as a first-in-human Phase 1a/1b study with up to six dose cohorts and a 25-patient expansion cohort. Initiation depends on timing and receipt of non-dilutive grant funding, so the financing disclosure and the clinical timetable remain closely connected.

Financing and listing facts

GT Biopharma stock is associated with a USD 7.8 million market capitalization as of October 1, 2026. The latest structured financial data show a second-quarter 2026 net loss of USD 4.52 million and cash of USD 4.96 million as of June 30, 2026.